CureVac’s Stock Market Journey Concludes with BioNTech Acquisition

CureVac NL0015436031

The independent chapter for Tübingen-based vaccine developer CureVac has closed. Investors are now awaiting the final administrative step of its takeover by BioNTech, following the suspension of its share trading on the Nasdaq. This week marks the definitive end of CureVac's tenure as a publicly listed company.

The process was set in motion by the completion of BioNTech's acquisition on December 18, 2025. The Mainz-based industry leader paid approximately €1.25 billion to consolidate the German mRNA sector. The agreed-upon share swap merges the resources of both firms, with a strategic emphasis on combining their intellectual property and patent portfolios.

Key transaction details include:
* Takeover finalized: December 18, 2025
* Trading halt: January 6, 2026
* Formal delisting: January 16, 2026
* Deal value: Roughly €1.25 billion

Trading Formally Suspended

Active trading of CureVac shares ceased on January 6, 2026. The listing was frozen at a final closing price of around $4.66 per share after the company notified regulators of the completed corporate reorganization. Market attention now turns to January 16, 2026, the effective date for the formal delisting, which will administratively remove the equity from the exchange.

A Shift for Shareholders

For existing investors, the focus shifts entirely from CureVac's specific volatility to the broader performance of BioNTech. Former shareholders now hold a direct stake in the Mainz company, whose research pipeline is concentrated in oncology and infectious diseases. The isolated price swings that characterized CureVac's stock are now a thing of the past.

The delisting, scheduled for Friday, will see the ticker symbol permanently disappear from trading boards. The operational integration of CureVac's technologies is now under BioNTech's management, concluding the story of CureVac as a standalone listed entity.